These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

5527 related items for PubMed ID: 507192

  • 1. The selection and characterization of an invasive variant of the B16 melanoma.
    Hart IR.
    Am J Pathol; 1979 Dec; 97(3):587-600. PubMed ID: 507192
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
    Boukerche H, Baril P, Tabone E, Bérard F, Sanhadji K, Balme B, Wolf F, Perrot H, Thomas L.
    Cancer Res; 2000 Oct 15; 60(20):5848-56. PubMed ID: 11059782
    [Abstract] [Full Text] [Related]

  • 9. Loss of metastatic responsiveness to cell shape modulation in a newly characterized B16 melanoma adhesive cell variant.
    Nabi IR, Raz A.
    Cancer Res; 1988 Mar 01; 48(5):1258-64. PubMed ID: 3342405
    [Abstract] [Full Text] [Related]

  • 10. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes.
    Yu HR, Schultz RM.
    Cancer Res; 1990 Dec 01; 50(23):7623-33. PubMed ID: 1701350
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the metastatic properties of B16 melanoma clones isolated from cultured cell lines, subcutaneous tumors, and individual lung metastases.
    Poste G, Doll J, Brown AE, Tzeng J, Zeidman I.
    Cancer Res; 1982 Jul 01; 42(7):2770-8. PubMed ID: 7083167
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Extraction of immunogenic and suppressogenic antigens from variants of B16 melanoma exhibiting low or high metastatic potentials.
    LeGrue SJ, Hearn DR.
    Cancer Res; 1983 Nov 01; 43(11):5106-11. PubMed ID: 6616449
    [Abstract] [Full Text] [Related]

  • 18. Comparative study of sialidase activity and G(M3) content in B16 melanoma variants with different metastatic potential.
    Sawada M, Moriya S, Shineha R, Satomi S, Miyagi T.
    Acta Biochim Pol; 1998 Nov 01; 45(2):343-9. PubMed ID: 9821865
    [Abstract] [Full Text] [Related]

  • 19. Metastatic potential and multidrug resistance correlation in the B16 melanoma system.
    Staroselsky AN, Mahlin T, Savion N, Klein O, Nordenberg J, Donin N, Michowitz M, Leibovici J.
    J Exp Ther Oncol; 1996 Jul 01; 1(4):251-9. PubMed ID: 9414412
    [Abstract] [Full Text] [Related]

  • 20. Prolonged in vitro culture modifies the surface lipid composition of murine melanoma cell lines.
    Moretti S, Montorfano G, Rapelli S, Berra B.
    Ital J Biochem; 1997 Dec 01; 46(4):187-94. PubMed ID: 9541865
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 277.